Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir
DOI:
https://doi.org/10.3889/oamjms.2022.7529Keywords:
Hepatitis C virus, Glomerular filtration rate, Sofosbuvir, DaclatasvirAbstract
BACKGROUND: According to the most recent Egyptian demographic health census, the estimated Hepatitis C virus (HCV) prevalence in the 15–59 age range was 14.7%. Globally, the incidence of renal impairment in HCV-positive individuals is 40% higher than in HCV-negative patients. HCV-induced renal impairment can range from mild-to-severe, and it frequently complicates the treatment outcome of HCV infection.
AIM: This study aimed to explore the changes in renal function in Egyptian HCV patients treated with a combination of Sofosbuvir (SOF) and Daclatasvir (DCV).
METHODOLOGY: Six hundred and eleven chronic HCV patients treated with SOF-DCV were enrolled. Patients were classified into three groups according to their baseline renal function: unimpaired group (estimated glomerular filtration rate [eGFR] ≥ 90 ml/min/1.73 m2), mildly impaired group (eGFR of ≥60–89 ml/min/1.73 m2), and moderately impaired group (eGFR of ≥30–59 ml/min/1.73 m2). Every month during treatment and at 24 weeks after treatment (sustained virological response 24), the eGFR level was evaluated.
RESULTS: Our findings indicated that the eGFR level was significantly increased (p < 0.001) in all groups during the treatment but subsequent decline (p < 0.001) in all groups was documented after 6 months of treatment. Multivariate analysis identified baseline renal impairment (<90 ml/min/1.73 m2, p < 0.001) and baseline anemia (p < 0.001) as independent risk factors for renal function deterioration at the end of treatment.
CONCLUSION: Clinical physicians should closely monitor renal function in patients treated with SOF-DCV. Furthermore, anemia therapy prior to SOF-DCV treatment should be recommended.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Li M, Wang P, Yang C, Jiang W, Wei X, Mu X, et al. A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease? Oncotarget. 2016;8(6):10692-702. https://doi.org/10.18632/oncotarget.12896 PMid:27793016 DOI: https://doi.org/10.18632/oncotarget.12896
Barsoum RS. Hepatitis C virus: From entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22(7):1840-8. https://doi.org/10.1093/ndt/gfm205 PMid:17478492 DOI: https://doi.org/10.1093/ndt/gfm205
Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD. Hepatitis C in Egypt past, present, and future. Int J Gen Med. 2016;10:1-6. https://doi.org/10.2147/IJGM.S119301 PMid:28053553 DOI: https://doi.org/10.2147/IJGM.S119301
Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: Real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421-31. https://doi.org/10.1111/apt.14428 PMid:29193226 DOI: https://doi.org/10.1111/apt.14428
Glead Siences Inc. Highlights of Prescribing Information. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.gilead.com%2F~%2Fmedia%2Ffiles%2Fpdfs%2Fmedicines%2Fliver-disease%2Fsovaldi%2Fsovaldi_pi.pdf&clen=641835&chunk=true
Lim TS, Ahn SH. Use of sofosbuvir in chronic kidney disease: Is it necessary? Clin Mol Hepatol. 2017;23:308-10. https://doi.org/10.3350/cmh.2017.0109 PMid:28948751 DOI: https://doi.org/10.3350/cmh.2017.0109
DeMaeyer E, Adiels-Tegman M. The prevalence of anaemia in the world. World Health Stat Q. 1985;38(3):302-16. PMid:3878044
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. https://doi.org/10.1159/000180580 PMid:1244564 DOI: https://doi.org/10.1159/000180580
Sanusi AA, Akinsola A, Ajayi AA. Creatinine clearance estimation from serum creatinine values: Evaluation and comparison of five prediction formulae in Nigerian patients. Afr J Med Med Sci. 2000;29(1):7-11. PMid:11379474
Fraser SD, Blakeman T. Chronic kidney disease: Identification and management in primary care. Pragmatic Obs Res. 2016;7:21-32. https://doi.org/10.2147/POR.S97310 PMid:27822135 DOI: https://doi.org/10.2147/POR.S97310
Chiu SM, Tsai MC, Lin CY, Chen CH, Lu SN, Hung CH, et al. Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. PLoS One. 2020;15(4):e0231102. https://doi.org/10.1371/journal.pone.0231102 PMid:32287280 DOI: https://doi.org/10.1371/journal.pone.0231102
Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, et al. Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol. 2017;12(10):1615-23. https://doi.org/10.2215/CJN.02510317 PMid:28882857 DOI: https://doi.org/10.2215/CJN.02510317
Faisal N, Bilodeau M, Aljudaibi B, Hirch G, Yoshida EM, Hussaini T, et al. Impact of sofosbuvir-based regimens for the treatment of hepatitis C after liver transplant on renal function: Results of a Canadian national retrospective study. Exp Clin Transplant. 2019;17(1):59-63. https://doi.org/10.6002/ect.2017.0201 PMid:29619910 DOI: https://doi.org/10.6002/ect.2017.0201
Tsai MC, Lin CY, Hung CH, Lu SN, Tung SY, Chien RN, et al. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. J Viral Hepat. 2019;26(12):1404-12. https://doi.org/10.1111/jvh.13193 PMid:31433885 DOI: https://doi.org/10.1111/jvh.13193
Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem. 1992;38(10):1933-53. PMid:1394976 DOI: https://doi.org/10.1093/clinchem/38.10.1933
Sugimoto R, Iwasa M, Hara N, Tamai Y, Yoshikawa K, Ogura S, et al. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res. 2018;48:337-44. https://doi.org/10.1111/hepr.12999 PMid:29115717 DOI: https://doi.org/10.1111/hepr.12999
Yoo JJ, Kim SG, Kim YS, Lee B, Lee MH, Jeong SW, et al. Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex. J Hepatol. 2019;70(5):847-54. https://doi.org/10.1016/j.jhep.2018.12.030 PMid:30630010 DOI: https://doi.org/10.1016/j.jhep.2018.12.030
Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Möckel M, et al. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009;88(1):124-30. https://doi.org/10.1016/j.athoracsur.2009.04.023 PMid:19559209 DOI: https://doi.org/10.1016/j.athoracsur.2009.04.023
Shin HP, Park JA, Burman B, Kozarek RA, Siddique A. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Clin Mol Hepatol. 2017;23(4):316-22. https://doi.org/10.3350/cmh.2016.0087 PMid:28827512 DOI: https://doi.org/10.3350/cmh.2016.0087
Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807-16. https://doi.org/10.1111/liv.13102 PMid:26923436 DOI: https://doi.org/10.1111/liv.13102
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Hala Abd El Maguid, Ahmed Heiba, Enass El Sayed, Hazem El-Hariri, Haythem Tolba, Muhammad Abdel Ghaffar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
